drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
A subcutaneous, full-length bispecific T‑cell–engaging monoclonal antibody (CD3×CD20) that binds CD20 on malignant B cells and CD3 on T cells to form an immune synapse, activate T cells, and induce targeted cytotoxic killing of CD20+ follicular lymphoma cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Antibodies, Bispecific
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Subcutaneous
drug_mechanism_of_action
A subcutaneous full-length bispecific anti-CD3×CD20 monoclonal antibody that simultaneously binds CD20 on malignant B cells and CD3 on T cells, forming an immune synapse to activate and redirect T-cell cytotoxicity for targeted killing of CD20-positive follicular lymphoma cells.
drug_name
Epcoritamab-bysp (Epkinly)
nct_id_drug_ref
NCT06112847